Wall Street Zen Downgrades Cassava Sciences to Sell

Analysts cite concerns over the company's lead drug candidate simufilam.

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Wall Street Zen, a research firm, has downgraded shares of Cassava Sciences (NASDAQ:SAVA) from a "hold" rating to a "sell" rating. This comes after another research firm, Weiss Ratings, reiterated a "sell (e+)" rating on the stock in late December.

Why it matters

Cassava Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease and other neurodegenerative disorders. The downgrade by Wall Street Zen raises further doubts about the prospects of the company's lead drug candidate, simufilam, which aims to address underlying mechanisms of neurodegeneration.

The details

In its report, Wall Street Zen cited concerns about simufilam and the overall outlook for Cassava Sciences. The downgrade comes as the company continues to face scrutiny over its research and development efforts.

  • Wall Street Zen issued the downgrade on Saturday, February 28, 2026.
  • Weiss Ratings reiterated its "sell (e+)" rating on Cassava Sciences on Friday, December 26th.

The players

Wall Street Zen

A research firm that has downgraded Cassava Sciences from a "hold" rating to a "sell" rating.

Weiss Ratings

A research firm that has reiterated a "sell (e+)" rating on Cassava Sciences.

Cassava Sciences

A clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease and other neurodegenerative disorders.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The downgrade by Wall Street Zen adds to the growing concerns surrounding Cassava Sciences and its lead drug candidate simufilam, raising questions about the company's ability to successfully develop treatments for Alzheimer's and other neurodegenerative disorders.